[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338309457{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER INT” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. LUIGI BUONAGURO” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”ISTITUTO NAZIONALE TUMORI “FONDAZIONE G. PASCALE“” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_single_image image=”146″ img_size=”medium” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”http://www.istitutotumori.na.it/”][/vc_column][vc_column width=”2/3″][vc_column_text]

IRCCS INT “Pascale” is the largest public Clinical Cancer Center in Southern Italy. The experimental and clinical units cover the full range of activities from basic research to innovative prevention, diagnosis and treatment approaches, with a strong translational – oriented strategy.

Luigi Buonaguro, MD is currently the Head of the Cancer Immunoregulation Lab of the Istituto Nazionale dei Tumori “Pascale” in Naples. Dr. Buonaguro has long-standing experience in development and evaluation of preventive and therapeutic vaccines. He is the Coordinator of the FP7-funded project “Cancer Vaccine development for Hepatocellular Carcinoma – HEPAVAC” (Grant Nr. 602893) www.hepavac.eu”.

He is the Coordinator of the HEPAMUT project. His lab will be fully involved in HCC neo – epitope discovery and immune validation.

Group members
Maria Tagliamonte, PhD
Annacarmen Petrizzo, PhD
Maria Lina Tornesello, PhD
Franco M. Buonaguro, MD[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”180″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]

SELECTED PUBLICATIONS

1) Tagliamonte et al., Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol. 2016; 39:103-113;

2) Buonaguro L & HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother. 2016; 65:93-99.

3) Tagliamonte et al., Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol Immunother. 2015; 64:1305-14

4) Buonaguro L et al., Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013; 59:897-903.

5) Tornesello et al., Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013; 102:74-83

[/vc_column][/vc_row]